SLC6A3 and schizophrenia: In the striatum, post-mortem studies report reduced levels of DAT binding in schizophrenia;57, 58 however, imaging studies indicated no change in striatal DAT binding in schizophrenia patients.9, 59, 60 Similar binding studies have not been carried out in the midbrain of schizophrenia patients in whom dopamine can be released in the somatodendritic field to regulate dopamine neuron activity via feedback inhibition.